Global Hyperphosphatemia Drugs Market To Grow At 16.64% Of Cagr By 2027

Triton Market Research presents their global hyperphosphatemia drugs market report segmented by Formulation (Calcium-based Phosphate Binders, Aluminum-based Phosphate Binders, Magnesium-based Phosphate Binders, Iron-based Phosphate Binders) and by geographical region (North America, Europe, Asia Pacific and rest of world) - discussing Industry Value Chain Analysis, Porter's 5 Force Analysis, Drivers, Restraints, Vendor Profiles, Global Market Size, Forecasts & Analysis (2019-2027).

Triton Market Research anticipates that the global hyperphosphatemia drugs market is evolving at 16.64% of CAGR during the estimated period of 2019-2027. The rise in the aging population, changing dietary habits and surging cases of osteoporosis is majorly contributing to the global hyperphosphatemia market. Moreover, increasing awareness among people is also boosting the market growth across the globe.

Hyperphosphatemia is an acute disease in which the level of phosphate is elevated in the blood. Phosphate binders are used to treat hyperphosphatemia, but they have adverse side effects on the patients, which is a huge turn down for the market demand. This leads to an increased need for effective treatment options, compelling vendors to extensively invest in the R&D of new drugs.

The global hyperphosphatemia drugs market is segmented into formulation, which consists of four key segments including, calcium-based phosphate binders, aluminum-based phosphate binders, magnesium-based phosphate binders, iron-based phosphate binders and other phosphate binders. The calcium-based phosphate binders is the largest segment in the formulation market. The aluminum-based phosphate binders were replaced by Calcium-based phosphate binders and are being utilization ever since the 1990s. They are majorly used as calcium supplements for the patients suffering from hyperphosphatemia.

Based on the geographical analysis, the market is divided into four major regions such as North America, Europe, Asia Pacific and the Rest of World. According to Triton market research, North American region is projected to contribute the highest revenue share in the global hyperphosphatemia drugs market by 2027. Growth in the geriatric population, alteration in the dietary consumption and increasing incidences of osteoporosis are the top reasons for this dominant growth in the region. Moreover, the APAC market is estimated to propel with the fastest developing CAGR throughout the forecasting years. The market in this region is backed by the growing population and increasing cases of chronic diseases.

The expanding research and development expenditure and absence of strict government regulation in the medical sector are the prominent factors intensifying the competitive rivalry in the hyperphosphatemia market. Furthermore, development of products and new product launch are the key strategies being applied by the players to sustain their presence in the market. Some of the established players in the hyperphosphatemia drugs market include Johnson and Johnson, Shire, Sanofi, Fresenius Medical Care and AMAG Pharmaceuticals.